- Multiple Indications for use - high-risk patients with equivocal mammograms, dense breasts, multifocality, scar tissue, implants, hormone replacement therapy, and palpable lesions not detected with mammography or ultrasound
- Provides physiological data not available from any other standard modality.
- Reduces physician & patient anxiety
- Allows a high degree of clinical confidence in negative studies
- Greatly reduce 6-month follow-up
- Excellent sensitivity for smaller non-palpable and/or medially located lesions
- Documented high sensitivity for the more difficult to detect DCIS and lobular carcinomas
- SmartShield™ decreases scatter radiation and immobilizes the breast without compression
- Can reduce false negative biopsy rate
- Improves medical diagnostic confidence
- Reduces potential liabilities
- Flexibility of the articulating arm design permits imaging in all mammographic views
- Mobile, all inclusive system - about the size of an ultrasound unit
- Same day evaluation - Quicker answers for your patient's peace of mind
- 78800, 78801, A9500 - standard nuclear medicine codes
- Average global reimbursement by Medicare - $400
- Short learning curve
- Direct correlation to mammograms
“Our MQSA audits from 2003 to 2006 tell a striking story.
Our practice averaged around 50 cancer diagnoses per year in 2003, 2004, and 2005. With the addition of BSGI in 2006 we found 93 cancers. We read a few more mammograms in 2006, but not the 5000 needed to achieve that increase on the usual mammographic statistics; it was clearly the impact of BSGI becoming a part of our institution’s breast cancer screening program. In addition, our PPV increased from 25% to 50%.”
~Clinical Results of BSGI: Ted Fogarty, MD – Radiologist Med Center One, Chairman of Radiology at University of North Dakota School of Medicine
© Copyright 2008 Dilon Technologies